Skip to main content Skip to search Skip to main navigation

EMA: New Q&A on Third Party Audits in the QP Declaration

EMA has published a Q&A on how to reflect third party audit(s) in part C of the QP declaration.

In part C of the QP declaration, information on audits as basis of QP Declaration of GMP Compliance should be given. Audit(s) of the active substance manufactured at the site(s) listed in PART A should be reported.

The Q&A includes a table where the manufacturing/import authorisation holder (MIAH) site (contract giver) and the audit body (contract acceptor) must be listed.

If the audit is undertaken by the MIAH, the auditing body column should be left empty. If the audit is performed by a third-party body (i.e. contract acceptor on behalf of the MIAH contract giver), this should be detailed as reflected in the contract.

In case the audit is performed on behalf of the MIAH by different entity/entities belonging to the same overall company, this should also be detailed in the auditing body column.

It is emphasised that in case the MIAH site does not perform the audit itself, the MIAH should be the contract giver. Consequently, the contract giver should always correspond to the MIAH site and the contract acceptor is expected to be the auditing body that actually performed the audit.


Source:

EMA: Questions and answers on how should third party audit(s) be reflected in part C of the QP declaration?


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next